Parexel Industry Insights

  1. Rethinking Patient Representation In Breast Cancer Trials For Better Outcomes 5/22/2026

    Broad patient representation in breast cancer trials is critical, and inclusive trial design improves data relevance, accelerates enrollment, and supports global approval and access.

  2. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

    In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

  3. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

  4. Timing And Data Are Critical To Winning BTD For Rare Disease Drugs 5/20/2026

    Breakthrough Therapy designation (BTD) can accelerate rare disease drug development—but timing and evidence are everything. Learn how to position your program for FDA success.

  5. Delivering Complex Oncology Trials At Scale 5/19/2026

    Parexel delivered two complex, global Phase III prostate cancer trials by aligning site selection, logistics, imaging workflows, and RAM regulatory expertise—achieving faster enrollment and on‑time execution.

  6. Strategies To Win Breakthrough Designation In Rare Disease Programs 3/31/2026

    Breakthrough designation can unlock faster paths for rare disease therapies. Learn how smart timing, compelling evidence, and early regulatory alignment can turn promising science into accelerated patient impact.

  7. 5 Strategies For Designing Successful Complex Rare Disease Trials 3/31/2026

    Rare disease trials demand inventive design. Uncover creative strategies that help sponsors overcome tiny populations, complex endpoints, and operational hurdles to advance meaningful breakthroughs.

  8. 5 RWE Approaches That Strengthen Precision Oncology 3/31/2026

    Real-world evidence is becoming vital in precision oncology. Discover five creative, practical ways sponsors can use RWE to fuel development, sharpen regulatory strategy, and strengthen market access.

  9. Accelerating Oncology Drug Development Through Innovative Designs 3/30/2026

    Adaptive and novel trial designs are redefining oncology development, powering faster decisions with smarter flexibility. Discover innovative approaches that elevate efficiency while safeguarding scientific rigor.

  10. Mastering Precision Oncology Start-Up: Reducing Screening Delays 3/30/2026

    Biomarker-driven trials create intricate screening hurdles. Explore creative, practical ways to accelerate start‑up, boost enrollment, and power precision oncology studies forward with greater speed.